




**Topics: US recovery marches on; why deaths are diverging from sharply rising infections; the American scientific trust gap vs the rest of the world; energy paper client Q&A**

The world is recovering rapidly from the COVID pandemic, erasing roughly half the 17% hit to global GDP that took place from January to April. Manufacturing and service sector surveys are rising around the globe, which we expect to continue in the months ahead. The US employment report beat expectations on new jobs (almost 5 million mostly private sector jobs) and on the unemployment rate, which fell to 11% from a peak level of 16%. The recovery in leisure and hospitality jobs is a positive sign given the impact on those sectors from the pandemic, and has roughly tracked our proprietary measure of hotel and restaurant credit/debit card spending.


The good news for **profits**: in prior post-recession periods, S&P 500 companies managed expenses aggressively and generated profits growth even before substantial increases in top-line revenues. This is referred to as "**operating leverage**", and is shown in the fourth chart (yellow segments show the substantial contribution of operating leverage to profits post recessions and other market declines).

**Estimated virus impact on global GDP**




Source: GS Investment Research. J. Hatzius, A. Tilton, D. Struyven. Jul 1, '20.

**Regional manufacturing & services business surveys**




Source: Markit PMI. June 2020.

**Leisure and hospitality: changes in spending and employment**



Source: Internal Chase data, BLS, JPMAM. June 29, 2020.

**Contribution to S&P 500 profits from operating leverage after recessions and other market declines, y/y % change**




Source: Standard and Poor's, JPMAM. Q1 2020.



**The US recovery is taking place despite the US now having the third highest infection rate in the world**, looking at the 50 largest countries by GDP<sup>1</sup>. The obvious question is whether this infection surge will derail the recovery. So far, most state countermeasures (shutting down gyms, bars, museums, water parks and some indoor dining) have been mild relative to restrictions imposed earlier.

**Infection levels for the largest 50 countries based on GDP**

Sorted by trailing 7 day average infection rate per mm people




Source: Johns Hopkins University, IMF, JPMAM. Countries shown represent 94% of World GDP. Asterisk denotes countries with infection levels over 225 per mm people. July 05, 2020

Here's some data on new infections over time. Compare the US and other high infection rate countries to Europe, and to Hubei (China) where COVID originated.

**New daily infections per mm people [Highly infected countries vs Europe and Hubei]**

7 day trailing avg



Source: Johns Hopkins University, IMF, JPMAM. July 05, 2020

<sup>1</sup> On our web portal, we also look at the highest infection rates based on the 50 largest countries by population (which comprise 87% of the world population). In that chart, the US ranks second only behind Brazil.




## US hospitalizations now catching up to rising infections, but deaths are not

The charts below show virus trends in the US and in **Hotspot** states. A couple of weeks ago, infections in the US and in Hotspot states were rising (gold line) while hospitalizations (blue line) and deaths<sup>2</sup> (red line) were not. This has now changed, with hospitalizations rising as well. Deaths are still falling, possibly due to improved medical interventions such as anti-coagulants and corticosteroids discussed in Section 4 of our web portal, but we need to wait before drawing firm conclusions since time lags may play a role as well.

Two weeks ago, some observers proposed that rising infections were just the result of **more young people circulating and not getting sick**. This appears to be *part* of what’s going on; a Vanderbilt study found that in Tennessee, COVID is now infecting a younger and less vulnerable population. This is depicted in the third chart; the primary reason for Tennessee’s lower recent Case Mix Index is the lower age of recently infected people. However, most US states do not regularly disclose time series of infection age distributions<sup>3</sup>. So, the “younger infection age” theory could be true more broadly but it’s hard to confirm, and now hospitalizations are rising as well as infections.


To be clear, lingering health consequences of COVID can be very debilitating for survivors of all ages: lung scarring, heart damage (cardiomyopathy and myocarditis), neurocognitive problems and abnormal blood clotting. Bottom line: you do not want to get this disease, no matter your age.

**US infections, hospitalizations and deaths, 7 day avg**




Source: CDC, COVID Tracking Project, JPMAM. July 06, 2020.

**Hotspot infections, hospitalizations and deaths, 7 day avg**



Source: CDC, COVID Tracking Project, JPMAM. July 06, 2020.

**Recent Tennessee infections less risky, mostly due to lower age of newly infected persons, COVID Risk Index**



Source: Vanderbilt School of Medicine. June 16, 2020.

<sup>2</sup> The temporary death spike in late June resulted from a one-time addition of “probable COVID deaths” in NY/NJ.

<sup>3</sup> A few states report cumulative distributions of infections by age; see Section 2 page 7 on our web portal.




Others have suggested that the spike in infections is just the result of more testing, **but that's not entirely the case either**: as shown below, Hotspot infections have been soaring while Hotspot testing rates are not that different from "Other States".

In any case, if falling deaths are now the barometer for state governments to remain open with only mild restrictions on bars and indoor dining, the US economy and equity markets may continue rising gradually through the summer, with the next litmus test being the possible market consequences of a Democratic Sweep in the fall (which we last wrote about on May 26). That's where we will focus our virus research in the weeks ahead: **deaths relative to rising infections and hospitalizations.**

**US new daily infections per mm people**


7 day trailing avg



Source: Johns Hopkins University, IMF, JPMAM. July 06, 2020

**US daily tests per mm people**

7 day trailing avg




Source: Johns Hopkins University, IMF, JPMAM. July 06, 2020

**Why is recent US virus performance so much worse than the rest of the world?**

While peak US mobility declines are not as large as in other countries, there are many countries with similar mobility declines that haven't experienced the infection surge now occurring in the US (first chart). And while most Hotspot mobility declines were smaller than in other US states, mobility doesn't consistently predict state infections either. As shown on our web portal, reopening dates also don't predict infections and hospitalizations. **There are no easy answers for why US infections have soared recently**; reopening dates, mobility changes and other empirically measured behaviors do not lead to higher infections in any statistically consistent way.

**Country mobility changes do not predict infections**


Categories: retail, restaurants, transit & workplace  
With most recent 7-day avg IPM (new daily infections per mm)



Source: Google, JPMAM. June 26, 2020.

**US mobility changes only partially explain infection rise**

Change in recent infections per mm people versus a month ago



Source: Google, JHU, JPMAM. June 26, 2020.



**Blinded by Science: the American scientific trust gap**


Are there other ways to explain the uniquely American virus surge?

- Despite the US leading the world in medical and biotech patents, and despite 22 of the top 40 universities for clinical research being located in the US (as per *US News & World Report*), **Americans rank below most of the world on interest and trust in science, on trust in science advice from government agencies and on belief in the importance, safety and utilization of vaccines.** See chart below for more details
- The **Trump administration** is not helping matters, according to 57 former US government scientists and public health officials of both parties. On Monday, the group called for a science-based approach to the pandemic and criticized the Trump administration for marginalizing science and expertise. See *"Statement From Former Gov. Scientists & Public Health Officials Calling for Science-based Response to the Serious and Growing COVID-19 Pandemic"*, posted on Medium.com
- The lack of trust in science gets magnified since Americans rank highest in the world on measures of **"individualism"** (i.e., the Geert-Hofstede cultural dimension index), which refers to those acting according to their own beliefs irrespective of the impact it may have on broader groups of people
- Grant Sanderson at 3Blue1Brown has highlighted visually<sup>4</sup> how it doesn't take a lot of non-social-distancing scientifically skeptical individuals to accelerate the spread of infection, and how there really isn't that much of a difference between 80% compliance and 50% compliance in a pandemic

These beliefs and behaviors may also partially explain why so many Americans, their representatives and some Wall Street strategists misunderstood what the rest of the developed world figured out in May: **how to shut down a pandemic.**

**How Americans rank globally on trust in science, medicine and vaccines**

Percentile rank, 144 countries



Source: Wellcome Trust/Gallup Global Science and Health Monitor. 2018.

<sup>4</sup> Click here for Grant's YouTube [visualization of a pandemic](#)



## **“What about...”: energy paper client Q&A**

Last week, we sent out our tenth annual energy paper which you can read [here](#). Each year, I receive follow-up questions from clients asking about topics that we did not address. Here are three of them.

### **What about low energy nuclear reactors (LENR) which convert hydrogen to helium and give off intense heat and no radiation?**

Vaclav and I agreed upfront that we would only cover energy sources which have reached, at the minimum, early stages of commercialization. There are many ideas that work in the lab but which are never commercialized (and thus have no real world impact), either due to cost or operational reasons. In contrast, we wrote about deep geothermal in Iceland this year, since while the technology is in its infancy, at least there is one site in the world which had been engaged in power generation using this new technology in a commercial setting. Similarly, we wrote about utility scale energy storage using lithium ion batteries despite its miniscule presence in the electricity food chain, since a handful of utilities are using them.

Currently, LENR does not meet this commercialization test. I will write about it when/if the concept is substantiated in the marketplace, and agree that if such reactions can be made to give off substantial levels of heat without radiation, that would be a major development in power/heat generation. Based on what I read, the first commercial LENR applications in the next 5 to 10 years could be in space heating with temperatures up to 200°C. To be clear, there's still plenty of skepticism on the idea: in May 2019, a team of researchers from the University of British Columbia, MIT, the University of Maryland, the Lawrence Berkeley National Laboratory and Google revisited LENR and failed to find evidence of fusion or heat.

### **What about renewable natural gas (RNG) made from landfills and other waste?**

Renewable natural gas is available without retrofitting of existing infrastructure. US RNG volumes are 200-300 mm gallons per year. According to Platts, the estimated potential from all US landfills is 2.9 bn gasoline gallon equivalents (GGE) per year, while NREL estimates potential for 4.8 bn GGE per year from landfills, agricultural waste, wastewater and other organic waste. In 2019, 142 bn gallons of motor gasoline were consumed in the US. So, even if RNG from all potential landfill and other sites were channeled into central processing facilities (which is expensive), RNG could at most offset ~2.5% of annual US gasoline demand. That would definitely be worth doing, and its impact would be even greater if paired with greater penetration of EVs. For investors, an RNG industry of 3-4 bn gallons per year could support the profitability of multiple new entrants. But I don't see its potential scope as “transformative” given RNG volume estimates. Germany has been converting waste to energy as well, using biogas from crops, waste and landfills to generate electricity rather than to make liquid fuel. This is not cheap, nearly 20 cents/kWh compared to 9 cents/kWh for onshore wind. There may be plenty of waste but gathering it from large areas to central processing facilities is energy-intensive itself.

### **What about electrifying the world's container ships?**

The first one is now in operation, carrying 120 twenty foot equivalent units (TEUs) at a speed of 6 knots for 30 nautical miles. Compare that to Maersk's Triple-E class ships which carry 150x as much cargo over distances 400x greater at speeds 3x-4x faster. What would it take to make an electric version of Maersk's ship, matching its speed and performance? Even when incorporating the higher efficiency of electric motors, using today's state of the art electric batteries with 300 Wh/kg of energy density, the electric version of the Maersk ship would have to dedicate 40% of its cargo capacity to the batteries themselves (obviously an economic non-starter). Or put it this way: an electric ship whose batteries and motors weighed no more than the fuel and diesel engine in today's container ships would need battery energy densities to improve by 10x vs current levels. Final bit of context: in the past 70 years, energy densities of the best commercial batteries haven't even quadrupled.



This report uses rigorous security protocols for selected data sourced from Chase credit and debit card transactions to ensure all information is kept confidential and secure. All selected data is highly aggregated and all unique identifiable information—including names, account numbers, addresses, dates of birth, and Social Security Numbers—is removed from the data before the report's author receives it.

Purpose of This Material: This material is for information purposes only. The views, opinions, estimates and strategies expressed herein constitutes Michael Cembalest's judgment based on current market conditions and are subject to change without notice, and may differ from those expressed by other areas of J.P. Morgan. **This information in no way constitutes J.P. Morgan Research and should not be treated as such.**

#### GENERAL RISKS & CONSIDERATIONS

Any views, strategies or products discussed in this material may not be appropriate for all individuals and are subject to risks. **Investors may get back less than they invested, and past performance is not a reliable indicator of future results.** Asset allocation / diversification does not guarantee a profit or protect against loss. Nothing in this material should be relied upon in isolation for the purpose of making an investment decision. You are urged to consider carefully whether the services, products, asset classes (e.g. equities, fixed income, alternative investments, commodities, etc.) or strategies discussed are suitable to your needs. You must also consider the objectives, risks, charges, and expenses associated with an investment service, product or strategy prior to making an investment decision. For this and more complete information, including discussion of your goals/situation, contact your J.P. Morgan team.

#### NON-RELIANCE

Certain information contained in this material is believed to be reliable; however, JPM does not represent or warrant its accuracy, reliability or completeness, or accept any liability for any loss or damage (whether direct or indirect) arising out of the use of all or any part of this material. No representation or warranty should be made with regard to any computations, graphs, tables, diagrams or commentary in this material, which are provided for illustration/reference purposes only. The views, opinions, estimates and strategies expressed in this material constitute our judgment based on current market conditions and are subject to change without notice. JPM assumes no duty to update any information in this material in the event that such information changes. Views, opinions, estimates and strategies expressed herein may differ from those expressed by other areas of JPM, views expressed for other purposes or in other contexts, and **this material should not be regarded as a research report.** Any projected results and risks are based solely on hypothetical examples cited, and actual results and risks will vary depending on specific circumstances. Forward-looking statements should not be considered as guarantees or predictions of future events.

Nothing in this document shall be construed as giving rise to any duty of care owed to, or advisory relationship with, you or any third party. Nothing in this document shall be regarded as an offer, solicitation, recommendation or advice (whether financial, accounting, legal, tax or other) given by J.P. Morgan and/or its officers or employees, irrespective of whether or not such communication was given at your request.

J.P. Morgan and its affiliates and employees do not provide tax, legal or accounting advice. You should consult your own tax, legal and accounting advisors before engaging in any financial transactions.

#### LEGAL ENTITY, BRAND & REGULATORY INFORMATION

In the **United States**, bank deposit accounts and related services, such as checking, savings and bank lending, are offered by **JPMorgan Chase Bank, N.A.** Member FDIC. **JPMorgan Chase Bank, N.A.** and its affiliates (collectively "JPMCB") offer investment products, which may include bank managed investment accounts and custody, as part of its trust and fiduciary services. Other investment products and services, such as brokerage and advisory accounts, are offered through **J.P. Morgan Securities LLC ("JPMS")**, a member of [FINRA](#) and [SIPC](#). Annuities are made available through Chase Insurance Agency, Inc. (CIA), a licensed insurance agency, doing business as Chase Insurance Agency Services, Inc. in Florida. JPMCB, JPMS and CIA are affiliated companies under the common control of JPM. Products not available in all states.

In **Luxembourg**, this material is issued by **J.P. Morgan Bank Luxembourg S.A. (JPMBL)**, with registered office at European Bank and Business Centre, 6 route de Treves, L-2633, Senningerberg, Luxembourg. R.C.S Luxembourg B10.958. Authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg S.A. is authorized as a credit institution in accordance with the Law of 5th April 1993. In the **United Kingdom**, this material is issued by **J.P. Morgan Bank Luxembourg S.A.– London Branch**. Prior to Brexit, (Brexit meaning that the UK leaves the European Union under Article 50 of the Treaty on European Union, or, if later, loses its ability to passport financial services between the UK and the remainder of the EEA), J.P. Morgan Bank Luxembourg S.A.– London Branch is subject to limited regulation by the Financial Conduct Authority and the Prudential Regulation Authority. Details about the extent of our regulation by the Financial Conduct Authority and the Prudential Regulation Authority are available from us on request. In the event of Brexit, in the UK, J.P. Morgan Bank Luxembourg S.A.– London Branch is authorised by the Prudential Regulation Authority, subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request. In **Spain**, this material is distributed by **J.P. Morgan Bank Luxembourg S.A., Sucursal en España**, with registered office at Paseo de la Castellana, 31, 28046 Madrid, Spain. J.P. Morgan Bank Luxembourg S.A., Sucursal en España is registered under number 1516 within the administrative registry of the Bank of Spain and supervised by the Spanish Securities Market Commission (CNMV). In **Germany**, this material is distributed by **J.P. Morgan Bank Luxembourg S.A., Frankfurt Branch**, registered office at Taunustor 1 (Taunusturm), 60310 Frankfurt, Germany, jointly supervised by the Commission de Surveillance du Secteur Financier (CSSF) and the European Central Bank (ECB), and in certain areas also supervised by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). In **Italy**, this material is distributed by **J.P. Morgan Bank Luxembourg S.A.– Milan Branch**, registered office at Via Catena Adalberto 4, Milan 20121, Italy and regulated by Bank of Italy and the Commissione Nazionale per le Società e la Borsa (CONSOB). In the **Netherlands**, this material is distributed by **J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch**, with registered office at World Trade Centre, Tower B, Strawinskylaan 1135, 1077 XX, Amsterdam, The Netherlands. J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch is authorised and regulated by the Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF in Luxembourg; J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch is also authorised and supervised by De Nederlandsche Bank (DNB) and the Autoriteit Financiële Markten (AFM) in the Netherlands. Registered with the Kamer van Koophandel as a branch of J.P. Morgan Bank Luxembourg S.A. under registration number 71651845. In **Denmark**, this material is distributed by **J.P. Morgan Bank Luxembourg, Copenhagen Br**, filial af J.P. Morgan Bank Luxembourg S.A. with registered office at Kalvebod Brygge 39-41, 1560 København V, Denmark. J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A. is authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A. is also subject to the supervision of Finanstilsynet (Danish FSA) and registered with Finanstilsynet as a branch of J.P. Morgan Bank Luxembourg S.A. under code 29009. In **Sweden**, this material is distributed by **J.P. Morgan Bank Luxembourg S.A. - Stockholm Bankfilial**, with registered office at Hamngatan 15, Stockholm, 11147, Sweden. J.P. Morgan Bank Luxembourg S.A. - Stockholm Bankfilial is authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central



Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg S.A., Stockholm Branch is also subject to the supervision of Finansinspektionen (Swedish FSA). Registered with Finansinspektionen as a branch of J.P. Morgan Bank Luxembourg S.A.. In **France**, this material is distributed by **JPMorgan Chase Bank, N.A. ("JPMCB"), Paris branch**, which is regulated by the French banking authorities Autorité de Contrôle Prudentiel et de Résolution and Autorité des Marchés Financiers. In **Switzerland**, this material is distributed by **J.P. Morgan (Suisse) SA**, which is regulated in Switzerland by the Swiss Financial Market Supervisory Authority (FINMA).

**In Hong Kong**, this material is distributed by **JPMCB, Hong Kong branch**. JPMCB, Hong Kong branch is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission of Hong Kong. In Hong Kong, we will cease to use your personal data for our marketing purposes without charge if you so request. In **Singapore**, this material is distributed by **JPMCB, Singapore branch**. JPMCB, Singapore branch is regulated by the Monetary Authority of Singapore. Dealing and advisory services and discretionary investment management services are provided to you by JPMCB, Hong Kong/Singapore branch (as notified to you). Banking and custody services are provided to you by JPMCB Singapore Branch. The contents of this document have not been reviewed by any regulatory authority in Hong Kong, Singapore or any other jurisdictions. This advertisement has not been reviewed by the Monetary Authority of Singapore. JPMorgan Chase Bank, N.A., a national banking association chartered under the laws of the United States, and as a body corporate, its shareholder's liability is limited.

JPMorgan Chase Bank, N.A. (JPMCBNA) (ABN 43 074 112 011/AFS Licence No: 238367) is regulated by the Australian Securities and Investment Commission and the Australian Prudential Regulation Authority. Material provided by JPMCBNA in Australia is to "wholesale clients" only. For the purposes of this paragraph the term "wholesale client" has the meaning given in section 761G of the Corporations Act 2001 (Cth). Please inform us if you are not a Wholesale Client now or if you cease to be a Wholesale Client at any time in the future.

JPMS is a registered foreign company (overseas) (ARBN 109293610) incorporated in Delaware, U.S.A. Under Australian financial services licensing requirements, carrying on a financial services business in Australia requires a financial service provider, such as J.P. Morgan Securities LLC (JPMS), to hold an Australian Financial Services Licence (AFSL), unless an exemption applies. **JPMS is exempt from the requirement to hold an AFSL under the Corporations Act 2001 (Cth) in respect of financial services it provides to you, and is regulated by the SEC, FINRA and CFTC under US laws, which differ from Australian laws.** Material provided by JPMS in Australia is to "wholesale clients" only. The information provided in this material is not intended to be, and must not be, distributed or passed on, directly or indirectly, to any other class of persons in Australia. For the purposes of this paragraph the term "wholesale client" has the meaning given in section 761G of the Act. Please inform us immediately if you are not a Wholesale Client now or if you cease to be a Wholesale Client at any time in the future.

This material has not been prepared specifically for Australian investors. It:

- may contain references to dollar amounts which are not Australian dollars;
- may contain financial information which is not prepared in accordance with Australian law or practices;
- may not address risks associated with investment in foreign currency denominated investments; and
- does not address Australian tax issues.

With respect to countries in **Latin America**, the distribution of this material may be restricted in certain jurisdictions. We may offer and/or sell to you securities or other financial instruments which may not be registered under, and are not the subject of a public offering under, the securities or other financial regulatory laws of your home country. Such securities or instruments are offered and/or sold to you on a private basis only. Any communication by us to you regarding such securities or instruments, including without limitation the delivery of a prospectus, term sheet or other offering document, is not intended by us as an offer to sell or a solicitation of an offer to buy any securities or instruments in any jurisdiction in which such an offer or a solicitation is unlawful. Furthermore, such securities or instruments may be subject to certain regulatory and/or contractual restrictions on subsequent transfer by you, and you are solely responsible for ascertaining and complying with such restrictions. To the extent this content makes reference to a fund, the Fund may not be publicly offered in any Latin American country, without previous registration of such fund's securities in compliance with the laws of the corresponding jurisdiction. Public offering of any security, including the shares of the Fund, without previous registration at Brazilian Securities and Exchange Commission-CVM is completely prohibited. Some products or services contained in the materials might not be currently provided by the Brazilian and Mexican platforms.

References to "J.P. Morgan" are to JPM, its subsidiaries and affiliates worldwide. "J.P. Morgan Private Bank" is the brand name for the private banking business conducted by JPM.

This material is intended for your personal use and should not be circulated to or used by any other person, or duplicated for non-personal use, without our permission. If you have any questions or no longer wish to receive these communications, please contact your J.P. Morgan team.

© 2020 JPMorgan Chase & Co. All rights reserved.